Brenus Pharma
Develops an off-the-shelf in vivo immunotherapy platform for solid tumors
€11MSeries A
Role not disclosedActivity from announced rounds
Noshaq is the Belgian investor identified by its own company list and by Novadip and Standing Ovation announcements.
Its recorded companies include Novadip’s regenerative cell therapies, Amyl’s antibodies against amyloid aggregates and Brenus’ off-the-shelf cancer immunotherapy. These programs pursue different clinical mechanisms and retain separate financing records.
Develops an off-the-shelf in vivo immunotherapy platform for solid tumors
Produces high-quality casein from whey permeates using precision fermentation